Cetuximab fails in second-line combination for recurrent NSCLC
Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Erbitux | Lung Cancer | Non-Small Cell Lung Cancer